There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
Results for performance period 4 of the Oncology Care Model just came out; what are the initial takeaways?
Practices that consistently have performed well continued to perform well. Practices that were trending in the right direction, but maybe haven’t made savings, a few of our practices have made savings, they made it over that finish line, and we’ve set that expectation that that is likely to happen given the good work that they were doing, and they’re seeing those results. And practices that haven’t performed well consistently, no surprise, didn’t get a very good report card with this reconciliation.
About half of our practices earned a PBP [performance-based payment] by this period, which is a performance period 4. That’s an increase in what we saw since performance period 3, which was about a third of our customer base earned a savings payment.
So, that was exciting news. I think overall, practices are happy with the results. I’m seeing a lot of smiling faces based on those results here, at [the Quality Cancer Care Alliance Fall 2019 Leadership Summit], which is great. But they’re a high-performing group, so they’re biased in that way, as they’re more progressive and stronger performing than some of the other practices that we work with. But good results overall, I think.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More